卡泊芬净与氟康唑预防儿童及年轻成人急性髓系白血病侵袭性真菌病效果的随机临床试验
这项多中心、随机、开放标签临床试验纳入517例3个月至30岁新诊断、复发或继发性急性髓系白血病患者,比较卡泊芬净与氟康唑预防中性粒细胞减少期间侵袭性真菌病的疗效。结果显示卡泊芬净组5个月侵袭性真菌病累积发生率显著低于氟康唑组,但研究因无效性分析提前终止,作者认为卡泊芬净可考虑用于预防,但解释受限。
要点
- 卡泊芬净组5个月侵袭性真菌病累积发生率为3.1%,低于氟康唑组的7.2%,差异显著。
- 卡泊芬净组侵袭性曲霉病累积发生率为0.5%,低于氟康唑组的3.1%,差异显著。
- 经验性抗真菌治疗和2年总生存率两组无显著差异。
核心结论
- 在儿童、青少年和年轻成人急性髓系白血病患者中,与氟康唑相比,卡泊芬净预防显著降低了侵袭性真菌病的发生率。
- 作者认为卡泊芬净可考虑用于侵袭性真菌病的预防,但研究解释受限于因非计划中期分析提示无效而提前终止。
研究设计与样本
- 多中心、随机、开放标签临床试验,在美国和加拿大115家机构开展(2011年4月至2016年11月,末次随访2018年6月30日)。
- 纳入年龄3个月至30岁的新诊断原发、复发或继发性急性髓系白血病患者,随机分配至卡泊芬净组(n=257)或氟康唑组(n=260),在每个化疗周期后的中性粒细胞减少期给予预防。
主要发现
- 共517例随机(中位年龄9岁,范围0-26岁;44%女性),508例(98%)完成试验。
- 确诊或临床诊断侵袭性真菌病事件共23例(卡泊芬净组6例 vs 氟康唑组17例),包括14例霉菌、7例酵母菌和2例未进一步分类的真菌。
- 5个月确诊或临床诊断侵袭性真菌病累积发生率:卡泊芬净组3.1%(95%CI 1.3%-7.0%) vs 氟康唑组7.2%(95%CI 4.4%-11.8%),log-rank检验总体P=0.03。
- 5个月确诊或临床诊断侵袭性曲霉病累积发生率:卡泊芬净组0.5%(95%CI 0.1%-3.5%) vs 氟康唑组3.1%(95%CI 1.4%-6.9%),log-rank检验总体P=0.046。
- 经验性抗真菌治疗(卡泊芬净组71.9% vs 氟康唑组69.5%,总体P=0.78)和2年总生存率(卡泊芬净组68.8% vs 氟康唑组70.8%,总体P=0.66)无统计学显著差异。
关键数值与推荐
- 主要结局为盲法中心评审裁定的确诊或临床诊断侵袭性真菌病。
- 次要结局包括侵袭性曲霉病、经验性抗真菌治疗和总生存率。
临床怎么用
- 作者认为卡泊芬净可考虑用于儿童、青少年和年轻成人急性髓系白血病患者的侵袭性真菌病预防。
- 研究解释受限于因非计划中期分析提示无效而提前终止。
局限性
- 研究因非计划中期分析提示无效而提前终止,限制了研究解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Children, adolescents, and young adults with acute myeloid leukemia are at high risk of life-threatening invasive fungal disease with both yeasts and molds. OBJECTIVE: To compare the efficacy of caspofungin vs fluconazole prophylaxis against proven or probable invasive fungal disease and invasive aspergillosis during neutropenia following acute myeloid leukemia chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, open-label, clinical trial enrolled patients aged 3 months to 30 years with newly diagnosed de novo, relapsed, or secondary acute myeloid leukemia being treated at 115 US and Canadian institutions (April 2011-November 2016; last follow-up June 30, 2018). INTERVENTIONS: Participants were randomly assigned during the first chemotherapy cycle to prophylaxis with caspofungin (n = 257) or fluconazole (n = 260). Prophylaxis was administered during the neutropenic period following each chemotherapy cycle. MAIN OUTCOMES AND MEASURES: The primary outcome was proven or probable invasive fungal disease as adjudicated by blinded central review. Secondary outcomes were invasive aspergillosis, empirical antifungal therapy, and overall survival. RESULTS: The second interim efficacy analysis and an unplanned futility analysis based on 394 patients appeared to have suggested futility, so the study was closed to accrual. Among the 517 participants who were randomized (median age, 9 years [range, 0-26 years]; 44% female), 508 (98%) completed the trial. The 23 proven or probable invasive fungal disease events (6 caspofungin vs 17 fluconazole) included 14 molds, 7 yeasts, and 2 fungi not further categorized. The 5-month cumulative incidence of proven or probable invasive fungal disease was 3.1% (95% CI, 1.3%-7.0%) in the caspofungin group vs 7.2% (95% CI, 4.4%-11.8%) in the fluconazole group (overall P = .03 by log-rank test) and for cumulative incidence of proven or probable invasive aspergillosis was 0.5% (95% CI, 0.1%-3.5%) with caspofungin vs 3.1% (95% CI, 1.4%-6.9%) with fluconazole (overall P = .046 by log-rank test). No statistically significant differences in empirical antifungal therapy (71.9% caspofungin vs 69.5% fluconazole, overall P = .78 by log-rank test) or 2-year overall survival (68.8% caspofungin vs 70.8% fluconazole, overall P = .66 by log-rank test) were observed. The most common toxicities were hypokalemia (22 caspofungin vs 13 fluconazole), respiratory failure (6 caspofungin vs 9 fluconazole), and elevated alanine transaminase (4 caspofungin vs 8 fluconazole). CONCLUSIONS AND RELEVANCE: Among children, adolescents, and young adults with acute myeloid leukemia, prophylaxis with caspofungin compared with fluconazole resulted in significantly lower incidence of invasive fungal disease. The findings suggest that caspofungin may be considered for prophylaxis against invasive fungal disease, although study interpretation is limited by early termination due to an unplanned interim analysis that appeared to have suggested futility. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01307579.
引用
- Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA. 2019. PMID: 31688884. doi:10.1001/jama.2019.15702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。